News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 678 results
May 2021
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical programBEOVU (brolucizumab-dbll) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one…
-
Media ReleaseNovartis commits to addressing racial disparities in breast cancer screening, treatment and care
-
Media ReleaseNovartis commits to addressing racial disparities in breast cancer screening, treatment and careBlack women with breast cancer are approximately 40% more likely to die compared to white women with breast cancer in the U.S.[1] - and are also more likely to be diagnosed at a later stage with…
-
Addressing health inequities starts by looking within
The Novartis US Foundation has partnered with the Institute for Healthcare Improvement to help healthcare systems better serve patients.
-
At-home app helps patients stay engaged and adherent to vision monitoring remotely
Novartis begins U.S. pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely.
-
Media ReleaseNovartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseNovartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus afliberceptIn KESTREL and KITE, BEOVU (brolucizumab-dbll) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in…
April 2021
-
Media ReleaseNovartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasisAt least 75% of children six years and older achieved PASI 90 at Week 52 when treated with Cosentyx in two pivotal studies1,2 Majority of children experienced improved health-related quality of…
-
Building clinical trial diversity for long-term equity
Vas Narasimhan reflects on how to increase diversity in clinical trials
-
Media ReleaseKesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMSKesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
-
Media ReleaseNovartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosisNew post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently…
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 57
- › Next page